{"id":534188,"date":"2021-09-02T17:03:05","date_gmt":"2021-09-02T21:03:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-02T17:03:05","modified_gmt":"2021-09-02T21:03:05","slug":"osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BRIDGEWATER, N.J., Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (\u201cOsmotica\u201d or the \u201cCompany\u201d), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James \u201cJD\u201d Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%;vertical-align: middle\">Date:<\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%;vertical-align: middle\">Monday, September 13, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">Time:<\/td>\n<td style=\"vertical-align: middle\">On Demand<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle\">Webcast:<\/td>\n<td style=\"vertical-align: middle\">\n            <a href=\"https:\/\/journey.ct.events\/view\/2feb327a-ca2a-4226-806e-84a8a49480db\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/journey.ct.events\/view\/2feb327a-ca2a-4226-806e-84a8a49480db<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=moAUvh4enqYG1E8egwfkrohRl7Dt63FbeLZxp_WWkFUMcP4gGG3EX_vgD2GfHUqqR3FvUaNuLm5dJ9iVCc6Gpw==\" rel=\"nofollow noopener\" target=\"_blank\">www.osmotica.com<\/a> under the \u201cInvestor &amp; News\u201d section.<\/p>\n<p align=\"justify\">\n        <strong>About Osmotica Pharmaceuticals plc<\/strong>\n      <\/p>\n<p>Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations. In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ<sup>\u00ae<\/sup> (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults. UPNEEQ was commercially launched September 2020 through RVL Pharmaceuticals, Inc., the Company\u2019s ophthalmic subsidiary, to a limited number of eye care professionals with commercialization operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties.<\/p>\n<p>\n        <strong>Investor and Media Relations for Osmotica Pharmaceuticals plc<\/strong><br \/>\n        <br \/>Lisa M. Wilson<br \/>In-Site Communications, Inc.<br \/>T: 212-452-2793<br \/>E: lwilson@insitecony.com<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YzcwZGRiOTItMjgzMy00NjlkLWE0ZTYtMTgzNzdlMjllNmY3LTExMDk0NTA=\/tiny\/Osmotica-Holdings-US-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (\u201cOsmotica\u201d or the \u201cCompany\u201d), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James \u201cJD\u201d Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows: Date: Monday, September 13, 2021 Time: On Demand Webcast: https:\/\/journey.ct.events\/view\/2feb327a-ca2a-4226-806e-84a8a49480db The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company\u2019s website at www.osmotica.com under the \u201cInvestor &amp; News\u201d section. About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534188","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (\u201cOsmotica\u201d or the \u201cCompany\u201d), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James \u201cJD\u201d Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows: Date: Monday, September 13, 2021 Time: On Demand Webcast: https:\/\/journey.ct.events\/view\/2feb327a-ca2a-4226-806e-84a8a49480db The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company\u2019s website at www.osmotica.com under the \u201cInvestor &amp; News\u201d section. About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient &hellip; Continue reading &quot;Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T21:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-02T21:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":234,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\",\"datePublished\":\"2021-09-02T21:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (\u201cOsmotica\u201d or the \u201cCompany\u201d), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James \u201cJD\u201d Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows: Date: Monday, September 13, 2021 Time: On Demand Webcast: https:\/\/journey.ct.events\/view\/2feb327a-ca2a-4226-806e-84a8a49480db The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company\u2019s website at www.osmotica.com under the \u201cInvestor &amp; News\u201d section. About Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient &hellip; Continue reading \"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T21:03:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-02T21:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":234,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=","datePublished":"2021-09-02T21:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTc3MiM0Mzg3ODAxIzIwOTc4Nzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/osmotica-pharmaceuticals-plc-to-present-at-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534188"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534188\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}